See more : Zhengzhou Tiamaes Technology Co., Ltd (300807.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Tempest Therapeutics, Inc. (TPST) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tempest Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Hazama Ando Corporation (HAZAF) Income Statement Analysis – Financial Results
- Chengdu Rainbow Appliance (Group) Shares Co., Ltd. (003023.SZ) Income Statement Analysis – Financial Results
- Shell plc (RDS-B) Income Statement Analysis – Financial Results
- HeXun Biosciences Co., Ltd. (6986.TWO) Income Statement Analysis – Financial Results
- Noble Engineering Group Holdings Limited (8445.HK) Income Statement Analysis – Financial Results
Tempest Therapeutics, Inc. (TPST)
About Tempest Therapeutics, Inc.
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 295.00K | 653.00K | 277.00K | 9.74M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 381.00K | 1.81M | 1.27M | 815.00K | 1.05M | 32.00K | 28.00K | 5.40M | 2.25M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -381.00K | -1.81M | -1.27M | -815.00K | -1.05M | -32.00K | 267.00K | -4.75M | -1.97M | 9.74M | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 90.51% | -727.11% | -711.91% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 17.50M | 22.53M | 17.17M | 14.39M | 27.84M | 14.43M | 14.53M | 21.64M | 18.43M | 21.78M | 15.80M | 6.32M | 1.17M |
| General & Administrative | 11.66M | 12.11M | 9.82M | 4.91M | 5.51M | 12.45M | 27.74M | 49.22M | 51.59M | 26.15M | 13.33M | 7.21M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 16.50M | -3.79M | -21.82M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 11.66M | 12.11M | 9.82M | 4.91M | 16.50M | 8.66M | 5.93M | 49.22M | 51.59M | 26.15M | 13.33M | 7.21M | 1.45M |
| Other Expenses | 0.00 | 549.00K | -34.00K | 0.00 | 0.00 | 0.00 | 4.03M | 5.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 29.16M | 34.64M | 26.99M | 19.30M | 44.35M | 23.08M | 20.45M | 70.86M | 70.03M | 47.93M | 29.13M | 13.53M | 2.62M |
| Cost & Expenses | 29.16M | 34.64M | 26.99M | 19.30M | 45.40M | 23.12M | 20.48M | 76.27M | 72.28M | 47.93M | 29.13M | 13.53M | 2.62M |
| Interest Income | 1.12M | 549.00K | 1.28K | 90.00K | 264.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 19.00K | 0.00 |
| Interest Expense | 1.45M | 1.62M | 1.28M | 0.00 | 0.00 | 134.00K | 0.00 | 659.00K | 436.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 381.00K | 1.81M | 1.27M | 815.00K | 1.05M | 32.00K | 28.00K | 2.24M | 1.29M | 450.00K | 231.00K | 0.00 | 0.00 |
| EBITDA | -28.78M | -32.28M | -25.72M | -18.39M | -43.52M | -27.01M | -84.27M | -79.82M | -71.86M | -49.07M | -28.81M | -13.53M | -2.62M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -6,933.56% | -11,236.45% | -25,528.16% | -504.06% | 0.00% | 0.00% | 0.00% |
| Operating Income | -29.16M | -34.64M | -26.99M | -19.30M | -45.40M | -23.12M | -20.48M | -75.61M | -72.00M | -47.93M | -29.13M | -13.53M | -2.62M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -6,943.05% | -11,579.17% | -25,992.42% | -492.38% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -334.00K | -1.07M | -1.32M | 90.00K | -21.19M | -4.06M | -64.10M | -1.05M | -1.15M | -1.59M | 90.00K | 19.00K | 0.00 |
| Income Before Tax | -29.49M | -35.71M | -28.30M | -19.21M | -44.57M | -27.18M | -84.59M | -82.06M | -73.14M | -49.52M | -29.04M | -13.51M | -2.62M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -28,673.22% | -12,566.46% | -26,405.78% | -508.68% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 1.07M | 1.25M | -90.00K | 1.00K | -169.00K | 67.00K | 201.00K | 75.00K | -1.59M | 90.00K | 0.00 | 0.00 |
| Net Income | -29.49M | -36.78M | -29.55M | -19.12M | -44.57M | -27.19M | -84.58M | -82.26M | -73.22M | -49.52M | -29.04M | -13.51M | -2.73M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -28,670.51% | -12,597.24% | -26,432.85% | -508.68% | 0.00% | 0.00% | 0.00% |
| EPS | -1.91 | -3.18 | -7.80 | -612.56 | -48.77 | -263.65 | -72.41K | -575.73 | -608.25 | -491.98 | -288.55 | -2.33 | 0.00 |
| EPS Diluted | -1.91 | -3.18 | -7.80 | -612.56 | -48.77 | -263.65 | -72.41K | -575.73 | -608.25 | -491.98 | -288.55 | -2.33 | 0.00 |
| Weighted Avg Shares Out | 15.42M | 11.55M | 3.79M | 31.21K | 913.78K | 103.14K | 1.17K | 142.88K | 120.38K | 100.65K | 100.65K | 0.00 | 0.00 |
| Weighted Avg Shares Out (Dil) | 15.42M | 11.55M | 3.79M | 31.21K | 913.78K | 103.14K | 1.17K | 142.88K | 120.38K | 100.65K | 100.65K | 0.00 | 0.00 |
What's Going On With Cancer-Focused Tempest Therapeutics Stock On Thursday?
Shares of Tempest Therapeutics Inc TPST are trading lower on Thursday, with a session volume of 21 million as per data from Benzinga Pro.
Why Is Tempest Therapeutics (TPST) Stock Up 45% Today?
Tempest Therapeutics (NASDAQ: TPST ) stock is heading higher on Thursday after the clinical-stage oncology company announced plans to show off new study data. Tempest Therapeutics will be holding a conference call at 8:30 a.m.
Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma
BRISBANE, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced the company plans to report new data from the global randomized Phase...
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., June 07, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that the Compensation Committee of the Company's Board of Directors granted one...
Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)
NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Tempest Therapeutics, Inc. (Nasdaq: TPST) concerning the Company and its directors' and officers' possible violations of state laws. If you own Tempest Therapeutics stock, would like to learn...
Tempest Reports First Quarter 2024 Financial Results and Provides Business Update
BRISBANE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today reported financial results for the quarter ended March 31, 2024, and provided a...
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that the Compensation Committee of the Company's Board of Directors granted one...
Tempest Therapeutics: Multiple 2024 Catalysts Make This A Must Watch
Tempest Therapeutics, Inc. achieved positive results from phase 1b/2 study using TPST-1120 + Tecentriq + Avastin for the treatment of patients with 1st-line HCC; Significant improvements in both confirmed and unconfirmed responses. Updated results from the phase 1b/2 study, using...
Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting
BRISBANE, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that collaborators at the Beth Israel Deaconess Medical Center (BIDMC) at Havard...
Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications
BRISBANE, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that Cancer Research Communications published positive clinical data from the dose-escalation Phase...
Source: https://incomestatements.info
Category: Stock Reports